Evaluation of Efficacy of Probiotics in Prevention of Candida Colonization in a PICU—A Randomized Controlled Trial*
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy of probiotics in prevention of Candida colonization in a PICU. DESIGN: Prospective double blinded, randomized controlled trial. SETTING: PICU of a tertiary care teaching hospital in north India. SUBJECTS: One hundred fifty children (106 boys, 44 girls), 3 months to 12 yrs old, on broad spectrum antibiotics for at least 48 hrs were randomized using computer-generated random numbers to receive probiotic mix (EUGI) (n = 75) or placebo (n = 75). INTERVENTION: Patients received one sachet twice a day of either probiotics or placebo for 7 days. Probiotics contained Lactobacillus acidophillus, Lactobacillus rhamnosum, Bifidobacterium longum, Bifidobacterium bifidum, Saccharomyces boulardi, Saccharomyces thermophilus, fructo-oligosaccharides; and placebo-contained lactose packed in similar-looking sachets. Rectal swabs for fungal culture were taken at day 0, 7, and 14 of enrollment. Primary outcome measure was prevalence of rectal colonization with Candida on day 14 postenrollment; secondary outcomes were growth of Candida in urine (candiduria) and blood (candidemia). Patients were followed until completion of 14 days study period or death of patient. RESULTS: Demographic and clinical variables were comparable in two groups. Prevalence of Candida colonization on day 0 was similar (15 of 75) in both the groups. On day 7, 27.9% (19 of 68) patients in the probiotic group and 42.6% (29 of 68) patients in the placebo group were colonized (relative risk 0.65; 95% confidence interval 0.41-1.05; p = 0.07), whereas, on day 14, colonization was observed in 31.3% (21 of 67) patients in the probiotic group and 50% (34 of 68) in the placebo group (relative risk 0.63; 95% confidence interval 0.41-0.96; p = 0.02). Thus, the relative reduction in prevalence of Candida colonization on day 7 and 14 in the probiotic group was 34.5% and 37.2%, respectively. The increase in number of colonized patients from day 0 to 7 and day 0 to 14 was significant in the placebo group (p = 0.004 and 0.001, respectively) but not in the probiotic group (p = 0.30 and 0.19, respectively; McNemar test). Candiduria was significantly less common in the probiotic group than in the placebo group (17.3% vs. 37.3%; relative risk 0.46; 95% confidence interval 0.26-0.82; p = 0.006). However, prevalence of candidemia did not differ significantly in two groups (1.6% in the probiotic group vs. 6.35% in placebo group; relative risk 0.46; 95% confidence interval 0.08-2.74; p = 0.39). CONCLUSIONS: Supplementation with probiotics could be a potential strategy to reduce gastrointestinal Candida colonization and candiduria in critically ill children receiving broad spectrum antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
León, C., Ruiz-Santana, S., Saavedra, P., Almirante, B., Nolla-Salas, J., Álvarez-Lerma, F., Garnacho-Montero, J., & León, M. Á. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000202208.37364.7d · Cited by 659 · cited 1×
“Candiduria is considered as a marker of heavy colonization (36) and a useful indicator of systemic candidiasis (37) particularly in critically ill children (38).”
Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523 · cited 1×
“Using prophylactic intravenous fluconazole, a three-fold reduction in rectal colonization was achieved in preterm neonates (19).”
Kennedy, M. J., & Volz, P. A. (1985) · Infection and Immunity · doi:10.1128/iai.49.3.654-663.1985 · Cited by 208 · cited 1×
“Normally intestinal bacterial flora inhibits Candida growth by competing for both adhesion sites and nutrients (32).”
Tortorano, A. M., Biraghi, E., Astolfi, A., Ossi, C., Tejada, M., Farina, C., Perin, S., Bonaccorso, C., Cavanna, C., Raballo, A., et al. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1261 · Cited by 116
Cited by
Effects of probiotics, prebiotics, and synbiotics on human health
Markowiak, P., & Śliżewska, K. (2017) · Nutrients · doi:10.3390/nu9091021 · Cited by 2,401
Dadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.028 · Cited by 332
Probiotics as antifungals in mucosal candidiasis
Matsubara, V. H., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw038 · Cited by 151
Graf, K., Last, A., Gratz, R., Allert, S., Linde, S., Westermann, M., Gröger, M., Mosig, A. S., Gresnigt, M. S., & Hube, B. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039719 · Cited by 83
Safety of probiotics and synbiotics in children under 18 years of age
van den Nieuwboer, M., Brummer, R. J., Guarner, F., Morelli, L., Cabana, M., & Claassen, E. (2015) · Beneficial Microbes · doi:10.3920/bm2014.0157 · Cited by 83
Metadata
- Authors
- Kumar, S., Bansal, A., Chakrabarti, A., & Singhi, S.
- Venue
- Critical Care Medicine
- Published
- 2013-02
- Volume
- 41
- Issue
- 2
- Pages
- 565-572
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W1980950318
- Cited by
- 98
- References
- 5
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Efficacy of Probiotics in Prevention of Candida Colonization in a PICU—A Randomized Controlled Trial*. https://app.cochat.ai/papers/10.1097/ccm.0b013e31826a409c
- The paper
- Kumar, S., Bansal, A., Chakrabarti, A., & Singhi, S. (2013). Evaluation of Efficacy of Probiotics in Prevention of Candida Colonization in a PICU—A Randomized Controlled Trial*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31826a409c
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.